Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels

IMPORTANCE: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy has been associated with cardiovascular benefits and a few adverse events; however, whether the comparative effectiveness and safety profiles vary with differences in baseline hemoglobin A(1c) (HbA(1c)) levels is unknown. OBJECTIV...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Andrea, Elvira, Wexler, Deborah J., Kim, Seoyoung C., Paik, Julie M., Alt, Ethan, Patorno, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989905/
https://www.ncbi.nlm.nih.gov/pubmed/36745425
http://dx.doi.org/10.1001/jamainternmed.2022.6664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989905/
https://www.ncbi.nlm.nih.gov/pubmed/36745425
http://dx.doi.org/10.1001/jamainternmed.2022.6664

Ejemplares similares